Finland awaits EMA position as official links AstraZeneca vaccine to blood clots

Yolanda Curtis
April 6, 2021

However, Marco Cavaleri, head of vaccine strategy at the EMA, told an Italian newspaper that full evaluation work was still "far from being completed" and that the risk-benefit ratio was still in favour of the vaccine.

He said that "we still do not know what causes this reaction", as reports accumulate of people across the world experiencing blood clots after receiving the jab developed by British-Swedish drug company AstraZeneca and Oxford University. He implied the link would be confirmed by the agency in the coming hours.

But it added that a causal link between clots and the vaccine is possible and the EMA is expected to provide an updated assessment on the investigation this week.

However, the EMA then conducted an investigation into the vaccine, and found that the benefits outweigh the risks and it should continue to be used.


So far in Ireland, over 203,000 doses of the AstraZeneca vaccine have now been administered.

Australian health officials have said they are taking the "potential risk very seriously", after the country recorded its first case of a blood clot following the vaccine.

Mr Cavaleri said they are still trying to understand where exactly this link comes from.

He added: "Among the vaccinated, there are more cases of cerebral thrombosis... among young people than we would expect".


The Pharmacy Guild of Australia, tasked to help with the rollout of the nationwide inoculation programme from May, said on Tuesday that slow domestic vaccine approvals and logistics issues will now push deliveries to June.

A government spokesman said yesterday: "The Oxford/AstraZeneca vaccine is safe, effective and has already saved thousands of lives in this country".

The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) confirmed that of those 30 people, seven had died as of 24 March.

In Germany, there have been 31 suspected cases of CVST - 19 accompanied by a drop in blood platelets - with nine deaths, according to the Paul-Ehrlich Institute.


The EMA last week recommended that countries should keep using the AstraZeneca vaccine because the benefits outweighed the risks, as countries including Italy suspended their rollout of the jab.

Other reports by iNewsToday

FOLLOW OUR NEWSPAPER